Abstract:Background: Epidemiological and cytological studies have found a potential protective function of Vitamin D3 in colitis-associated colorectal cancer (CAC). In this study, we aim to decipher this effect in an azoxymethane (AOM) and dextran sulfate sodium (DSS) induced CAC mouse model and explore the underlying mechanism primarily focusing on the β-catenin signaling pathway. Methods: In vitro, colon cancer cell line SW480 were treated with 1,25(OH)2D3 at different concentrations (1, 10, 50 and 100nmol/L) for 24, 48 and 72h and then quantified for proliferation. Transcriptional activity and the protein level of β-catenin were determined in SW480 cells both nontreated (control) and treated with 100nmol/L 1,25(OH)2D3 for 48h. Same assay was applied to SW480 cells with FOXM1 and nVDR siRNA knockdowns separately. In animal experiment, C57BL/6 mice were divided into 6 groups. Group 1 was the naïve control given only saline. Group 2 to 6 were given AOM (12.5mg/kg) by intraperitoneal injection and 2.5% DSS by gastric lavage sequentially to establish CAC model. Group 2 was the model control; Group 3 to 5 received Vitamin D3 at 15, 30, 60IU/g/w before AOM/DSS treatment, while Group 6 (post-dose group) received 60IU/g/w VitD3 5 days after DSS intake. Mice were sacrificed after 14 weeks. Macroscopic and pathologic evaluations were carried out to assess the severity of CAC. The mRNA and protein levels of β-catenin were also detected. Results: The proliferation of SW480 cells was significantly inhibited by 1,25(OH)2D3 both dose-dependently and time-dependently (p<0.05). 1,25(OH)2D3 significantly decreased the transcriptional activity of β-catenin in SW480 cells by promoting the nuclear export of β-catenin (p<0.05) without affecting the mRNA and protein levels of β-catenin, which could be recovered by knocking down either FOXM1 or nVDR. In mice, Vitamin D intervention groups (G4,5,6) showed a lower tumor number and smaller tumor load than model control (G2) (p<0.05). However, there was no significant difference between the high dose group (G5) and post-dose group (G6). In addition, Vitamin D intervention groups presented lower β-catenin mRNA level than model control (p<0.05). The amount of nuclear β-catenin decreased as the VitD3 dose increased. Finally, the protein expression level of β-catenin was much less in the high dose group (G5) than model control (p<0.05). Conclusions: 1,25(OH)2D3 downregulates the transcriptional activity of β-catenin by expelling β-catenin out of nucleus and therefore severely dampens the proliferation of SW480 human colon cancer cells. In mice model, VitD3 treatment successfully inhibits the progression from AOM/DSS-induced colitis to colorectal cancer potentially by downregulating the activity of β-catenin signaling pathway.

1,25(OH)2D3 attenuates TGF-β1/β2-induced increased migration and invasion via inhibiting epithelial-mesenchymal transition in colon cancer cells.

1,25(OH)2D3 Attenuates IL-1β-Induced Epithelial-to-Mesenchymal Transition Through Inhibiting the Expression of Lnctcf7.

1α,25(OH)2D3 Suppresses the Migration of Ovarian Cancer SKOV-3 Cells through the Inhibition of Epithelial–Mesenchymal Transition

1α,25-Dihydroxyvitamin D Downregulates Adipocyte Impact on Breast Cancer Cell Migration and Adipokine Release

1,25(OH)2D3 inhibits Lewis lung cancer cell migration via NHE1‐sensitive metabolic reprograming

TGFβ1I1 Suppressed Cell Migration and Invasion in Colorectal Cancer by Inhibiting the TGF-β Pathway and EMT Progress.

1 α ,25 (OH)2D3 inhibits proliferation of gastric cancer cell line by arresting cell cycle

1α,25-hydroxyvitamin D/VDR suppresses stem-like properties of ovarian cancer cells by restraining nuclear translocation of β-catenin

Antiproliferative Effects of 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells

Knockdown of CYP24A1 Aggravates 1α,25(OH)2D3-Inhibited Migration and Invasion of Mouse Ovarian Epithelial Cells by Suppressing EMT

Β-Elemene Regulates Epithelial-Mesenchymal Transformation and Inhibits Invasion and Metastasis of Colorectal Cancer Cells

Tumor-suppressive Effects of 1, 25-Dihydroxyvitamin D3 in Gastric Cancer Cells.

1, 25(Oh)(2)D-3 Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion Of Inflammatory Cytokines From Immunocytes

1,25-Dihydroxyvitamin D3 Affects Gastric Cancer Progression by Repressing BMP3 Promoter Methylation.

Bevacizumab and anexelekto inhibitor, TP-0903 inhibits TGF-β1-induced epithelial-mesenchymal transition of colon cancer cells

1Α,25(oh) 2D 3 Decreases Expression of Immune Checkpoint Receptors and Enhances Anti-Tumor Immunity of Human Cytotoxic T Cells

P083 the Protective Role of Vitamin D3 on Colitis-Associated Colorectal Cancer in a Mouse Model

1,25-Dihydroxyvitamin D3 Preserves Intestinal Epithelial Barrier Function from TNF-α Induced Injury Via Suppression of NF-kB P65 Mediated MLCK-P-MLC Signaling Pathway.

Effect of 1,25 dihydroxyvitamin D3 on the proliferation and epithelial-mesenchymal transition in cancer stem cells derived from anaplastic thyroid carcinoma

1α,25-dihydroxyvitamin D3 inhibits tumor necrosis factor-α induced activation of human umbilical vein endothelial cells via NF-κB signaling pathway

Ginsenoside Rb2 Inhibits Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Suppressing TGF-β/Smad Signaling.